INCY Quote, Financials, Valuation and Earnings

Exelixis has a net margin of 9.36% compared to Incyte's net margin of 21.87%. Incyte's return on equity of 0.75% beat Exelixis's return on equity of 20.97%.

Incyte has a consensus price target of $79.30, signalling upside risk potential of 14.93%. On the other hand Exelixis has an analysts' consensus of $33.56 which suggests that it could grow by 0.79%. Given that Incyte has higher upside potential than Exelixis, analysts believe Incyte is more attractive than Exelixis.

Incyte has a beta of 0.706, which suggesting that the stock is 29.419% less volatile than S&P 500. In comparison Exelixis has a beta of 0.534, suggesting its less volatile than the S&P 500 by 46.575%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are larger than Exelixis quarterly revenues of $539.5M. Incyte's net income of $106.5M is lower than Exelixis's net income of $118M. Notably, Incyte's price-to-earnings ratio is 493.36x while Exelixis's PE ratio is 21.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.68x versus 4.82x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of 9.36% compared to Incyte's net margin of -236.04%. Incyte's return on equity of 0.75% beat Insmed's return on equity of --.

Incyte has a consensus price target of $79.30, signalling upside risk potential of 14.93%. On the other hand Insmed has an analysts' consensus of -- which suggests that it could grow by 27.83%. Given that Insmed has higher upside potential than Incyte, analysts believe Insmed is more attractive than Incyte.

Incyte has a beta of 0.706, which suggesting that the stock is 29.419% less volatile than S&P 500. In comparison Insmed has a beta of 1.122, suggesting its more volatile than the S&P 500 by 12.219%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are larger than Insmed quarterly revenues of $93.4M. Incyte's net income of $106.5M is higher than Insmed's net income of -$220.5M. Notably, Incyte's price-to-earnings ratio is 493.36x while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.68x versus 31.29x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 9.36% compared to Incyte's net margin of 18.95%. Incyte's return on equity of 0.75% beat Merck &'s return on equity of 29.26%.

Incyte has a consensus price target of $79.30, signalling upside risk potential of 14.93%. On the other hand Merck & has an analysts' consensus of $130.34 which suggests that it could grow by 29.4%. Given that Merck & has higher upside potential than Incyte, analysts believe Merck & is more attractive than Incyte.

Incyte has a beta of 0.706, which suggesting that the stock is 29.419% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Incyte pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are smaller than Merck & quarterly revenues of $16.7B. Incyte's net income of $106.5M is lower than Merck &'s net income of $3.2B. Notably, Incyte's price-to-earnings ratio is 493.36x while Merck &'s PE ratio is 20.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.68x versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 9.36% compared to Incyte's net margin of 25.23%. Incyte's return on equity of 0.75% beat Pfizer's return on equity of 4.63%.

Incyte has a consensus price target of $79.30, signalling upside risk potential of 14.93%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.1%. Given that Pfizer has higher upside potential than Incyte, analysts believe Pfizer is more attractive than Incyte.

Incyte has a beta of 0.706, which suggesting that the stock is 29.419% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.33% to investors and pays a quarterly dividend of $0.42 per share. Incyte pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are smaller than Pfizer quarterly revenues of $17.7B. Incyte's net income of $106.5M is lower than Pfizer's net income of $4.5B. Notably, Incyte's price-to-earnings ratio is 493.36x while Pfizer's PE ratio is 35.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.68x versus 2.54x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.